(Law360.com) An organization with close ties to hedge fund manager Kyle Bass filed a petition with the Patent Trial and Appeal Board on Monday seeking an inter partes review of Biogen MA Inc.’s patent covering the multiple sclerosis drug Tecfidera, about a month after the board refused to institute an IPR of the same patent.
Hedge Fund Manager Again Targets Biogen’s MS Drug Patent
This entry was posted in Syndicated. Bookmark the permalink.
